Prostate Cancer : Episode 4

Video

Episode 4 - Treatment Guidelines and Economic Considerations

During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.

However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.

To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.


Related Videos
Matias Sanchez, MD
Sandra Cuellar, PharmD
Milind Desai, MD
Masanori Aikawa, MD
James Chambers, PhD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Adam Colborn, JD
Cesar Davila-Chapa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo